ClinicalTrials.gg
CompletedNCT01486823Updated Dec 11, 2012

Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects

A Phase 1 interventional study of MLDL1278A and MLDL1278A in Healthy, sponsored by BioInvent International AB. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-11.

Sponsored by BioInvent International AB · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a study in healthy volunteers designed to investigate the PK following intravenous and subcutaneous administration of MLDL1278A (also known as BI-204). The bioavalialbility of MLDL1278A after subcutaneous administration will be determined.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

BioInvent International AB is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males/females aged 18 to 55 years inclusive at screening;
  • Subjects who are between 18.0 and 30.0 kg/m2 (BMI) inclusive and weigh between 55.0 and 100.0 kg inclusive;

Exclusion criteria

Exclusion Criteria:

  • Any disease or disorder (past or present), which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results of the study, or the subject's ability to participate in the study;
  • Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, coagulation, urinalysis, vital signs or at baseline, which, in the opinion of the investigator, may put the subject at risk because of his participation in the study;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Cohort A

    Drug: MLDL1278A

  • Experimental
    Cohort B

    Drug: MLDL1278A

Interventions

  • Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.

  • Single subcutaneous dose of 360 mg MLDL1278A.

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve (AUC) of MLDL1278A.

    Time frame: Up to 70 days post administration.

Secondary outcomes

  1. Peak plasma concentration (Cmax) of MLDL1278A.

    Time frame: Up to 70 days post administration.

  2. Plasma clearance (CL) of MLDL1278A.

    Time frame: Up to 70 days post administration.

  3. Number of participants with an anti therapeutic antibody (ATA) response.

    Time frame: Up to 140 days post administration.

  4. Number of participants with adverse events.

    Time frame: Up to 140 days post administration.

07

Study locations

1 site
  • Quintiles Drug Research Unit at Guy's Hospital
    London, SE1 1YHR, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2011
First posted
Dec 7, 2011
Start
Nov 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Last update
Dec 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01486823
Lead sponsor
BioInvent International AB
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 7, 2011
Start date
Nov 2011
Primary completion
Jul 2012
Completion
Jul 2012
Last update
Dec 11, 2012

Study contacts

Darren Wilbraham, MD
principal investigator · Quintiles, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLDL1278A

Start the discussion